Tag Archives: Cerebrospinal Fluid (CSF) Biomarkers

Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)

Posted on June 28, 2017 by Dementia and Elderly Care News

Summary The Deep and Frequent Phenotyping Study aims to discover new ways of diagnosing dementia, ideally decades before the symptoms become apparent in order to give future drug treatments the best chance of working. The Deep and Frequent Phenotyping Study … Continue reading →

Posted in Alzheimer's Society, BBC News, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, Mental Health, Models of Dementia Care, National, NIHR, Quick Insights, UK, Universal Interest | Tagged Ageing Population, Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Amnestic Mild Cognitive Impairment (a-MCI), Amnestic Mild Cognitive Impairment (aMCI), Applications of Big Data, BBC Radio, BBC Radio 4, BBC's World At One Programme, Big Data Analytics, Big Data Funding and Research, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Neuropsychological Test Automated Battery (CANTAB), Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Deep and Frequent Phenotyping Study (DFP), Deep and Frequent Phenotyping; Combinatorial Biomarkers of Dementia, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, DFP Study Team, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Gait and Cognition, Gait Changes, Gateway to Research (GtR), Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, Join Dementia Research, Join Dementia Research: Clinical Trials Matchmaker Service, Join Dementia Research: Recruitment Onto Dementia Studies, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurobiology of Aging (Journal), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Open Data and Big Data, Ophthalmological Assessments, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, PharmaCog Consortium, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Clare Mackay: Imaging Neuroscience at the University of Oxford, Professor Lynn Rochester: Clinical Ageing Research Unit at Newcastle University, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Publicly-Funded UK Big Data Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Screening Tools for Amnestic Mild Cognitive Impairment (a-MCI), Surrogate Biomarkers of Neurodegeneration, Translational Research, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology) | Leave a comment

Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)

Posted on November 4, 2016 by Dementia and Elderly Care News

Summary Early results from a Phase I trial indicate that the BACE1 inhibitor Verubecestat may effectively reduce β-amyloid formation in human patients with Alzheimer’s Disease. This appears to confirm previous trials with rats, monkeys and healthy young human adults. As … Continue reading →

Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)

Posted on August 22, 2016 by Dementia and Elderly Care News

Summary The Deep and Frequent Phenotyping Study will explore improvements in biomarker research and the development of tests to detect Alzheimer’s Disease early on. This research programme will be funded by the National Institute of Health Research (NIHR) and the … Continue reading →

Posted in Alzheimer's Society, Charitable Bodies, Commissioning, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, National, NIHR, Quick Insights, UK, Universal Interest | Tagged Alterations in Movement and Walking (“Gait”) Assessments, Alzheimer's Disease: Early Detection by Brain Scan, Alzheimer’s Disease Biomarkers, Aridhia, AstraZeneca / MedImmune, Berry Consultants, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Biomarkers Research Programmes, Blood and Urine Biomarkers, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Scans, Cambridge Cognition, Cerebrospinal Fluid (CSF) Biomarkers, Clinical Assessments, Cognitive Assessments / Screening Tools, Conversion to Dementia From Prodromal Disease, CSF Biomarkers, Deep and Frequent Phenotyping Study, Dementia Research, Dementia Research Funding, Dementias Platform UK, Dementias Platform UK (DPUK), Dementias Platform UK: MRC, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, DPUK: Dementias Platform UK, Dr Rob Buckle: Director of Science Programmes at MRC, Drug Trials Failure Rate, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, EEG: Electroencephalography, Effectiveness of Early Detection and Treatment, Electroencephalogram (EEG) Brain Scans, Electroencephalography (EEG), Exprodo, Gait and Cognition, Gait Changes, Global Dementia Research, Global Leadership, Hypothetical Prodromes of Dementia, Imanova, Imperial College London, IXICO, Kings College London, Magnetic Resonance Imaging (MRI) Scan, Magnetoencephalography (MEG), Medical Research Council (MRC), Medical Research Council (UK), National Institute of Health Research (NIHR), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Newcastle University, Non-Invasive Biomarkers, Ocular Manifestations in Neurodegenerative Diseases, Ophthalmological Assessments, Optos, Participation in Research, Participation in Research Studies, Partnership and Collaboration, Patient and Public Participation, Positron Emission Tomography (PET), Pre-Clinical Genotype-Phenotype Predictors of Alzheimer's Disease, Prodromal Alzheimer's Disease, Professor Chris Whitty: Chief Scientific Adviser at Department of Health, Professor Simon Lovestone: Lead Researcher and Professor of Translational Neuroscience at University of Oxford, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Proteomic Analysis, Proteomics, Public Participation in Research, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Funding, Retina as Early Biomarker of Neurodegeneration, Retinal Biomarkers, Retinal Changes as Surrogate Biomarker for Alzheimer's Disease, Retinal Ganglion Cells (RGCs), Retinal Manifestations of Alzheimer's Disease, Sage Bionetworks, Surrogate Biomarkers of Neurodegeneration, Translational Research, TrialSpark, University College London, University of Cambridge, University of Edinburgh, University of Manchester, University of Oxford, Volunteers, Walking Pattern (Gait), Wearable Devices, Wearables (Technology), West London Mental Health Trust / Imperial College London | 1 Comment

Diagnosis, Screening, Assessment and Symptoms-Related Systematic Reviews and Meta-Analyses

Posted on August 20, 2014 by Dementia and Elderly Care News

Recent reviews and meta-analyses on the broad topics diagnosis, screening and assessment are listed below. Some of these articles may be available freely (according to local circumstances). A suitable Athens password, a journal subscription or payment for access may be … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Models of Dementia Care, Systematic Reviews | Tagged Addenbrooke's Cognitive Examination (ACE), Addenbrooke's Cognitive Examination-Revised (ACE-R), Assessment and Diagnosis, Biomarkers, Blood-Based Biomarkers, Breaking Bad News, Case Identification and Screening, Cerebrospinal Fluid (CSF) Biomarkers, Cognitive Screening, CSF Biomarkers, Dementia Diagnosis, Dementia Screening, Diagnosis and Assessment, Diagnosis and Referral, Diagnosis and Support, Differential Diagnosis, Disclosure of Diagnosis, fMRI, Functional Magnetic Resonance Imaging (fMRI), Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), Plasma Biomarkers, Screening, Screening for Cognitive Impairment, Screening for Dementia, Systematic Review of Screening for Dementia in the Older Population | Leave a comment

Concerning the Diagnostic Accuracy of Plasma and CSF Biomarkers (Cochrane Database)

Posted on August 2, 2014 by Dementia and Elderly Care News

Summary This systematic review investigates the diagnostic accuracy of blood plasma and CSF Aß levels for detecting patients with mild cognitive impairment (MCI) and who are likely to progress to Alzheimer’s Disease or other types of dementia. The accuracy of … Continue reading →

Posted in Charitable Bodies, Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Systematic Reviews, UK | Tagged Aß40, Aß42, ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Alzheimer's Association, Alzheimer's Disease and Related Disorders Association (Now the Alzheimer's Association), Alzheimer’s Disease Biomarkers, Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Apolipoprotein E, Asymptomatic Alzheimer’s Disease, Beta-Amyloid, Beta-Amyloid Plaques, Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood-Based Biomarkers, Cambridge Institute of Public Health, Cambridge Institute of Public Health: Cambridge University, Candidate Blood Proteome Markers, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Cochrane Database, Cochrane Database of Systematic Reviews, Cochrane Dementia and Cognitive Improvement Group, Cochrane Register of Diagnostic Test Accuracy Studies, Cognitive Impairment, Cognitive Response to Progression of Pathophysiology, Conversion to Dementia From Prodromal Disease, CSF Aß Levels, CSF Aβ, CSF Biomarkers, CSF Tau, Dementia Screening, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV), Diagnostic Test Accuracy, Early Detection of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Differential Diagnosis, Early Screening, Fluid and Imaging Biomarkers, Imperial College London, Institute of Public Health: University of Cambridge, β-amyloid, β-Amyloid 1-42 (Aβ42), MCI: Mild Cognitive Impairment, Mild Cognitive Impairment (MCI), National Institute of Neurological and Communicative Disorders and Stroke, Neurodegeneration, NINCDS-ADRDA Criteria, NINCDS-ADRDA: National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer Disease and Related Disorders Association, Plasma Biomarkers, Plasma Proteins, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Progression of Mild Cognitive Impairment to Dementia, Systematic Reviews and Meta-Analyses, Transition from Cognitive Impairment to Dementia, University of Birmingham, University of Cambridge, University of Oxford, University of Oxford: Radcliffe Department of Medicine, University of Western Australia, US Alzheimer's Association, Western Australian Centre for Health and Ageing (WACHA) | Leave a comment

Early Diagnosis of Alzheimer’s Disease Using Spinal Fluid? (NHS Choices / Cell Reports)

Posted on March 27, 2014 by Dementia and Elderly Care News

Summary A recent diagnostic study has investigated the possibility of diagnosing Alzheimer’s Disease, years before disease onset, using cerebrospinal fluid (CSF). The technique for identifying people with Alzheimer’s Disease would be based on detecting very small amounts of abnormal (misfolded) … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), In the News, International, NHS Digital (Previously NHS Choices), Quick Insights, Universal Interest | Tagged Aβ-PMCA, Alzheimer's Association, Alzheimer's Disease: Diagnosis, Alzheimer’s Early Screening, Amprion Inc., Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Assessment and Diagnosis, Behind the Headlines, Beta-Amyloid, Beta-Amyloid Plaques, Biochemical Diagnosis of Alzheimer's Disease, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Carlo Besta Neurological Institute, CART Foundation, Cell Reports, Centro Dino Ferrari, Cerebrospinal Fluid, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, CSF, CSF Aβ, CSF Aβ(1-42), CSF Biomarkers, CSF Tau, Cyclic Amplification of Amyloid-Beta Misfolding, Dementia Screening, Department of Neurology: University of Texas Medical School at Houston, Detection of Synthetic Ab Oligomers by Ab-PMCA, Differential Diagnosis, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Screening, Improving Diagnosis, IRCC Ospedale Policlinico, IRCCS Foundation, Italian Ministry of Health, Italy, Lumbar Punctures, Milan, Misfolded Aβ Oligomers, Misfolded Proteins, Mitchell Center for Alzheimer's Disease and Related Brain Disorders: University of Texas Medical School at Houston, Mitchell Foundation, MIUR, Neurodegeneration, Neurodegenerative Diseases, Neurology Unit: Università di Milano, Non-AD Neurodegenerative Diseases (NANDs), Nondegenerative Neurological Diseases (NNDs), Protein Misfolding Cyclic Ampliﬁcation (PMCA), Screening, Spinal Fluid, Timely Diagnosis, Università di Milano, University of Texas Medical School at Houston, USA | Leave a comment

Recent Systematic Reviews and Meta-Analyses on Diagnosis, Screening, Assessment and Symptoms

Posted on January 12, 2014 by Dementia and Elderly Care News

Some of the following articles are available freely. The full-text of the other articles may need a suitable Athens password, a journal subscription or payment for access. The Bibliographic Citations Zhang, J. Zhang, CH. Li, RJ. [et al] (2013). Accuracy … Continue reading →

Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Quick Insights, Systematic Reviews | Tagged Alzheimer's Disease: Diagnosis, Assessment and Diagnosis, Biomarkers, Blood Proteome Markers, Cerebral Vascular Disease, Cerebrospinal Fluid (CSF), Cerebrospinal Fluid (CSF) Biomarkers, Dementia Diagnosis, Dementia Screening, Diagnosis and Assessment, Diagnosis of Alzheimer's Disease, Disclosure of Diagnosis, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Emotions (Upon Disclosure of Diagnosis, Experiences of Diagnosis, GRECOG-VASC Study Group, Impact of Diagnosis, Improving Diagnosis, Mild Cognitive Impairment (MCI), Prodromal Alzheimer's Disease, Screening, Screening for Dementia, Systematic Reviews and Meta-Analyses, Urinary AD7c-NTP | Leave a comment

Tag Archives: Cerebrospinal Fluid (CSF) Biomarkers

Earlier Diagnosis Research: the Deep and Frequent Phenotyping Study (BBC News / GtR)

Early Promising Signs in Verubecestat Human Drug Trial – Since Dashed (NHS Choices / Science Translational Medicine / Translational Neurodegeneration / Biospace Inc)

Deep and Frequent Phenotyping Study: Dementia Early Detection and Biomarkers Research Programme (MRC / NIHR)

Diagnosis, Screening, Assessment and Symptoms-Related Systematic Reviews and Meta-Analyses

Recent Systematic Reviews and Meta-Analyses on Diagnosis, Screening, Assessment and Symptoms

Recent Posts

Archives

Categories

Google Translate (100+ Languages)

Recommended Sites